SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : PFE (Pfizer) How high will it go?
PFE 25.07-0.1%3:59 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: BigKNY3 who wrote (3898)7/3/1998 5:27:00 PM
From: BigKNY3  Read Replies (3) of 9523
 
Wow, I almost missed this in the same Andrew Barry Barron's article. A counter remark from Christina Heuer!

BigKNY3

Christina Heuer, Smith Barney's drug analyst, says investors are overreacting to the Viagra prescription data. "People are missing the big picture. Pfizer has a brilliant outlook and phenomenal earnings momentum." A Viagra bull, Heuer estimates that sales of the drug will hit $2 billion next year and $5 billion worldwide in 2002. Pfizer, she says, will be powered by Viagra, Lipitor and Celebra, the first of a new class of drugs being developed to treat arthritis pain.

Heuer, a long-time Pfizer fan, sees the company earning $2.15 a share this year, $2.70 in 1999. Her price target for the stock is $150 by the end of 1999.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext